Translational Development Acquisition Corp.
TDAC
$10.60
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 378.96% | 67.20% | 56.78% | 11.96% | -59.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 378.96% | 67.20% | 56.78% | 11.96% | -59.38% |
| Operating Income | -378.96% | -67.20% | -56.78% | -11.96% | 59.38% |
| Income Before Tax | 8,961.28% | 968.97% | 723.89% | 390.74% | 85.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8,961.28% | 968.97% | 723.89% | 390.74% | 85.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8,961.28% | 968.97% | 723.89% | 390.74% | 85.21% |
| EBIT | -378.96% | -67.20% | -56.78% | -11.96% | 59.38% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 1,788.37% | 259.84% | 204.16% | 142.29% | 85.64% |
| Normalized Basic EPS | 1,748.15% | 259.69% | 203.99% | 142.13% | 85.60% |
| EPS Diluted | 1,788.37% | 259.84% | 204.16% | 142.29% | 85.64% |
| Normalized Diluted EPS | 1,748.15% | 259.69% | 203.99% | 142.13% | 85.60% |
| Average Basic Shares Outstanding | 398.75% | 339.15% | 228.92% | 118.69% | 8.46% |
| Average Diluted Shares Outstanding | 398.75% | 339.15% | 228.92% | 118.69% | 8.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |